BDTX
NASDAQ · Biotechnology
Black Diamond Therapeutics I
$1.95
+0.03 (+1.56%)
Open$1.94
Previous Close$1.92
Day High$1.99
Day Low$1.91
52W High$4.94
52W Low$1.60
Volume—
Avg Volume631.5K
Market Cap116.92M
P/E Ratio—
EPS$-0.76
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,742.1% upside
Current
$1.95
$1.95
Target
$35.92
$35.92
$30.62
$35.92 avg
$44.24
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 72.92M | 26.85M | 24.30M |
| Net Income | 23.30M | 2.09M | 2.49M |
| Profit Margin | 32.0% | 7.8% | 10.3% |
| EBITDA | 13.38M | 3.87M | 3.57M |
| Free Cash Flow | — | 2.98M | 2.09M |
| Rev Growth | — | +10.3% | +9.4% |
| Debt/Equity | — | 0.41 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |